TORONTO, July 8 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced
today that it has submitted new provisional patents for inventions relating to
its Semen Sexing Technology(TM) (SST(TM)).
SST(TM) allows commercial breeders to pre-determine the sex of livestock
offspring resulting from artificial insemination. For example, dairy farmers
will use SST(TM) to breed primarily female animals for their milking herds.
Likewise, the technology will assist beef producers in producing primarily
male animals required for meat production. The global artificial insemination
market is currently valued at over $2.5 billion.
The new patent submissions describe new inventions, devised during the
course of SST(TM) development, that would significantly strengthen Microbix'
proprietary process for separating X and Y chromosome-containing sperm.
Potential benefits include lower production costs, higher yields, and higher
Microbix reported earlier this year that it was going to invest more time
in building on its findings as additional sex specific proteins had been
discovered. "This was time well spent, as evidenced by today's announcement,"
said William J. Gastle, Chairman and CEO of Microbix.
"We plan to continue this vital work which is expanding our technology
portfolio and our avenues for commercialization," Gastle added. "SST(TM) has
the potential to play an important role in helping to feed an increasingly
hungry world by promoting the efficient growth of beef and dairy industries."
Established in 1988, Microbix specializes in developing proprietary
biological technologies and commercializing them through global partners. The
company has previously announced the signing of exclusive and nonexclusive
licensing agreements for SST(TM) technology with partners worldwide. The
company recently announced the signing of a definitive agreement for the
construction of a $200 million influenza virus vaccine facility with the
government of Hunan Province in China, incorporating its VIRUSMAX(TM)
Technology which significantly boosts the yield of influenza virus from eggs.
Microbix is also pursuing the production and marketing of Urokinase, a
thrombolytic biologic that can be used as a catheter clearing drug and has
potential in new cancer drug combination.
This press release contains forward-looking statements, which are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements, such as the
risks associated with obtaining patent protection in various jurisdictions,
the risks associated with efficacy and reliability of the technology, and the
risks associated with developing and commercializing the technologies. These
forward-looking statements represent the Company's judgment as of the date of
this press release. The Company disclaims any intent or obligation to update
these forward-looking statements.
For further information:
For further information: visit www.microbix.com or contact: Phil
Casselli, President, Microbix Biosystems Inc., (416) 234-1624 x 224; Robert
Stephens, PR POST, (416) 777-0368